85 related articles for article (PubMed ID: 31602329)
1. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age.
Petrillo A; Pappalardo A; Calabrese F; Tirino G; Pompella L; Ventriglia J; Laterza MM; Caterino M; Sforza V; Iranzo V; Biglietto M; Orditura M; Ciardiello F; Conzo G; Molino C; De Vita F
J Gastrointest Oncol; 2019 Oct; 10(5):910-917. PubMed ID: 31602329
[TBL] [Abstract][Full Text] [Related]
2.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
4. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer.
Rehman H; Chi J; Hakim N; Goyal SP; Olazagasti C; Jose J; Moriarty L; Saif MW
Therap Adv Gastroenterol; 2020; 13():1756284820974912. PubMed ID: 33281939
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
6. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.
Ahn DH; Krishna K; Blazer M; Reardon J; Wei L; Wu C; Ciombor KK; Noonan AM; Mikhail S; Bekaii-Saab T
Ther Adv Med Oncol; 2017 Feb; 9(2):75-82. PubMed ID: 28203300
[TBL] [Abstract][Full Text] [Related]
7. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
8. Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma.
Domadia K; Goel V; Koyyala VPB; Patnaik N; Chaudhari K; Raina S; Doval DC; Talwar V
South Asian J Cancer; 2022 Jan; 11(1):31-35. PubMed ID: 35833047
[TBL] [Abstract][Full Text] [Related]
9. Alternating Gemcitabine/Nab-Paclitaxel (GA) and 5-FU/Leucovorin/Irinotecan (FOLFIRI) as First-Line Treatment for De Novo Metastatic Pancreatic Cancer (MPC): Safety and Effect.
Schroeder BA; Mandelson MT; Picozzi VJ
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067292
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
Zhang W; Du C; Sun Y; Yang L; Cui C; Jiang Z; Wang C; Wang J; Zhou A
Cancer Chemother Pharmacol; 2018 Oct; 82(4):655-660. PubMed ID: 30054709
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma.
Scheithauer W; Kornek G; Prager G; Stranzl N; Laengle F; Schindl M; Friedl J; Klech J; Roethlin S; Zielinski C
J Gastrointest Oncol; 2016 Apr; 7(2):234-8. PubMed ID: 27034791
[TBL] [Abstract][Full Text] [Related]
12. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer.
Mie T; Sasaki T; Takeda T; Okamoto T; Hamada T; Ishitsuka T; Yamada M; Nakagawa H; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672308
[TBL] [Abstract][Full Text] [Related]
13. The
Palacio S; Hosein PJ; Reis I; Akunyili II; Ernani V; Pollack T; Macintyre J; Restrepo MH; Merchan JR; Rocha Lima CM
J Gastrointest Oncol; 2018 Feb; 9(1):135-139. PubMed ID: 29564179
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.
Martín AJ; Alfonso PG; Rupérez AB; Jiménez MM
Oncol Lett; 2016 Jul; 12(1):727-730. PubMed ID: 27347207
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
[TBL] [Abstract][Full Text] [Related]
16. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
17. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma.
Peddi PF; Cho M; Wang J; Gao F; Wang-Gillam A
J Gastrointest Oncol; 2013 Dec; 4(4):370-3. PubMed ID: 24294508
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
Zhang Y; Hochster H; Stein S; Lacy J
Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study.
Chen Z; He Y; Ding C; Chen J; Gu Y; Xiao M; Li Q
Onco Targets Ther; 2023; 16():923-935. PubMed ID: 37965584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]